Back to today’s briefing

Story perspectives

Trump Tackles Drug Pricing Amid Vaccine Trust Crisis

2/21/2025

48 4

Summary

Story summary

PhRMA is set to meet with President Trump to tackle the contentious issue of drug pricing reforms. While skepticism looms among the public, Trump and health secretary Robert F. Kennedy Jr. are determined to reshape healthcare policies. Simultaneously, experts are calling for a pause on COVID-19 vaccines, stirring fears about potential side effects and eroding public trust in health initiatives.

History

Historical Context

PhRMA's upcoming meeting with President Trump on drug pricing reforms echoes past healthcare debates, notably the 2003 Medicare Part D legislation, which barred Medicare from negotiating drug prices. This has led to soaring costs in the U.S. compared to countries with price controls. The current skepticism about COVID-19 vaccines also reflects historical public distrust in health initiatives, reminiscent of past vaccine controversies.

1 of 2

Story summary

PhRMA is set to meet with President Trump to tackle the contentious issue of drug pricing reforms. While skepticism looms among the public, Trump and health secretary Robert F. Kennedy Jr. are determined to reshape healthcare policies. Simultaneously, experts are calling for a pause on COVID-19 vaccines, stirring fears about potential side effects and eroding public trust in health initiatives.

1 / 2